These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28458317)

  • 1. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome.
    Yamada Y; Abe R; Okano Y; Miyakawa Y
    Intern Med; 2017; 56(9):1085-1088. PubMed ID: 28458317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
    Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
    J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
    Sengul Samanci N; Ayer M; Ergen A; Ozturk S
    Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
    Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late renal recovery after treatment over 1 year post-onset in an atypical hemolytic uremic syndrome: a case report.
    Kuroki Y; Mitsuiki K; Nakagawa K; Tsuruya K; Katafuchi R; Hirakata H; Nakano T
    BMC Nephrol; 2020 Jun; 21(1):236. PubMed ID: 32571244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome.
    Ono M; Ohashi N; Namikawa A; Katahashi N; Ishigaki S; Tsuji N; Isobe S; Iwakura T; Sakao Y; Tsuji T; Kato A; Fujigaki Y; Shimizu A; Yasuda H
    Intern Med; 2018 Jun; 57(11):1617-1623. PubMed ID: 29434134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atypical hemolytic uremic syndrome in an elderly patient successfully treated with eculizumab].
    Fukasawa C; Ooishi S; Kumagai T; Koshiisi M; Sueki Y; Nakajima K; Mitsumori T; Yoshida Y; Kato H; Nangaku M; Miyata T; Kirito K
    Rinsho Ketsueki; 2018; 59(2):182-186. PubMed ID: 29515071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome.
    Ashida A; Matsumura H; Shimono A; Fujii Y; Yamazaki S
    Clin Exp Nephrol; 2023 Feb; 27(2):161-170. PubMed ID: 36336723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
    Haskin O; Falush Y; Davidovits M
    Pediatr Nephrol; 2019 Dec; 34(12):2601-2604. PubMed ID: 31520126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review.
    de Souza RM; Correa BHM; Melo PHM; Pousa PA; de Mendonça TSC; Rodrigues LGC; Simões E Silva AC
    Pediatr Nephrol; 2023 Jan; 38(1):61-75. PubMed ID: 35864223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.
    Sharma S; Pradhan M; Meyers KE; Le Palma K; Laskin BL
    Clin Nephrol; 2015 Sep; 84(3):181-5. PubMed ID: 25816809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atypical hemolytic uremic syndrome. Report of two cases treated with Eculizumab].
    Tagle R; Rivera G; Walbaum B; Sepúlveda RA
    Rev Med Chil; 2018 Feb; 146(2):254-259. PubMed ID: 29999163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.